Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $14.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 344.44% from the company’s current price.
Evaxion Biotech A/S Price Performance
EVAX opened at $3.15 on Friday. The company has a fifty day moving average price of $3.01 and a two-hundred day moving average price of $3.31. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80. The firm has a market capitalization of $17.04 million, a PE ratio of -0.73 and a beta of -0.27. Evaxion Biotech A/S has a 52 week low of $2.26 and a 52 week high of $13.61.
Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.14). The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million. During the same period in the previous year, the company earned ($2.10) EPS. As a group, analysts anticipate that Evaxion Biotech A/S will post -0.24 earnings per share for the current year.
Institutional Inflows and Outflows
Evaxion Biotech A/S Company Profile
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.
Featured Articles
- Five stocks we like better than Evaxion Biotech A/S
- Options Trading – Understanding Strike Price
- Triple Witching: The Market’s Quarterly Rollercoaster
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 4 Stocks Set to Benefit from Recent Interest Rate Cuts
- What is the Australian Securities Exchange (ASX)
- Autohome’s Dividend and Buyback Make It a Strong EV Play
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.